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uantification of
yocardial Flow Reserve
sing Positron Emission Imaging
he Journey to Clinical Use*
ob S. B. Beanlands, MD,
aria Cecilia Ziadi, MD, Kathryn Williams, MS
ttawa, Ontario, Canada
“A journey of a thousand miles begins with a single step”
—Lao-tzu, The Way of Lao-tzu
Chinese philosopher (604 BC to 531 BC) (1)
f the many advantages of positron emission tomography
PET) imaging, its ability to quantify biological parameters
s often identified as the most important. Yet, data linking
ET-derived parameters to outcomes are often lacking. In
his issue of the Journal, Herzog et al. (2) present one of the
rst studies to evaluate the prognostic value of PET-derived
uantification of coronary flow reserve (CFR) using 13N-
mmonia (13NH3) in patients with suspected ischemia and
he first to evaluate its added prognostic value compared
ith relative myocardial perfusion imaging (MPI). Such
valuation is a key step on the journey to establish the
linical role of this approach.
See page 150
The coronary circulation is a dynamic vascular bed that
atches blood flow with oxygen requirements governed by
utoregulatory mechanisms. In myocardium supplied by an
bstructive coronary artery stenosis, blood flow is main-
ained through such mechanisms until there is a more
ritical stenosis or there is an increase in demand, which
esults in a supply-demand imbalance leading to ischemia.
s such, myocardial blood flow (MBF) has long been
ecognized as a key physiological parameter in cardiovascu-
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
From the Molecular Function and Imaging Program and the National Cardiac
ET Centre, Division of Cardiology, and the Cardiovascular Research Methods
entre of the University of Ottawa Heart Institute, Ottawa, Ontario, Canada. Dr.
eanlands consults for DRAXIMAGE; has received grant funds from GE Health-
are and MDS NORDION; and is a Career Investigator supported by the Heart and
troke Foundation of Ontario (HSFO). Dr. Ziadi is a Research Fellow supported byw
niversity of Ottawa International Fellowship Program, the Molecular Function and
maging Program (HSFO grant #PRG6242), and the Division of Cardiology.ar health and disease (3). Accordingly, MPI has evolved as
diagnostic method to evaluate the hemodynamic signifi-
ance of obstructive coronary artery disease (CAD). The
ole of MPI in diagnosis and prognostication is well
stablished for single-photon emission computed tomogra-
hy (SPECT) (4) and more recently, PET (5–7). PET is
lso capable of flow quantification in absolute terms (ml/
in/g) during stress and rest, the ratio of which is the CFR
8,9). Measurement of CFR may have a role in early
etection of coronary atherosclerotic disease (microvascular
ysfunction) (9) or reveal the presence of diffuse obstructive
AD (9,10). Although this approach has been firmly
stablished in research settings for almost 3 decades (11), its
idespread role in the clinical arena has not been realized.
ven so, there is growing interest in its potential added
alue due to the current limitations of relative MPI in these
ettings.
In the journey to translate PET quantitative flow analysis
nto a useful routinely applied clinical tool, several steps
eed to be accomplished. First, the parameter must have
athophysiological relevance in relation to disease. Subse-
uently, methods to measure the parameter must be vali-
ated and reproducible, available, easy to apply, and must
emonstrate added value for diagnostic or prognostic appli-
ations that affect therapy decisions leading to improved
utcomes.
Gould et al. (3) described the value of CFR as an index of
he functional severity of coronary stenosis, supporting its
athophysiological relevance (12). Resting MBF remains
ormal until there is an 80% to 85% diameter stenosis; CFR
ecreases progressively if the stenosis is 40% (12). Flow
uantification with PET has been well validated and shown
o be reproducible (13–15). With expanding application in
ancer, PET is becoming more widely available. List mode
cquisition now enables simultaneous gating with dynamic
cquisitions for kinetic modeling, making routine flow
uantification possible. However, whether flow quantifica-
ion with PET provides added value to current MPI has not
een widely evaluated to date. The study by Herzog et al.
2) is a timely step in this regard.
Herzog et al. (2) included 229 patients, of whom: 69%
ere males, 66% had known CAD, 62% had angina, and
2% were on anti-ischemic medications. This is a relevant
ohort for evaluation, though slightly different than other
tudies, which included more women (5,6) but fewer pa-
ients with known CAD (40% to 53%). The authors used
3NH3, a well-validated tracer for flow quantification.
Patients with abnormal CFR had significantly worse
utcomes than those with normal CFR: 45.1% versus 23.6%
ajor adverse cardiac events and 20.6% versus 6.3% cardiac
eath, respectively, over a mean follow-up of 5.5 years. This
dds to the growing literature supporting the prognostic
alue of PET-derived flow and CFR in patients with
onatherosclerotic cardiomyopathies (16,17) and in patients
ith severe CAD not amenable to revascularization with
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Quantification of Flow Reserve Using PET July 7, 2009:157–9eft ventricular dysfunction (18). To date, such CFR data
ave not been shown to alter management decisions that
ffect symptoms, quality of life, or outcomes.
The study by Herzog et al. (2) suggests that CFR yields
dded value for patients with abnormal perfusion and
nables risk stratification with normal perfusion. In patients
ith abnormal perfusion, an impaired CFR was associated
ith higher rates of major adverse cardiac events and cardiac
eath. So, it seems that a reduction of CFR in this subgroup
f patients affords incremental prognostic information.
owever, the study was too small to determine if the
ncremental increases in the summed stress score on MPI
ay have yielded similar results. Still, if the CFR results can
e further validated, this parameter has the potential to alter
ecisions specifically regarding revascularization.
Conversely, in patients with normal perfusion, a normal
FR was considered to yield a warranty period of 3 years
ompared with those with abnormal CFR. The small
ample size limits detection of differences beyond this point.
his abnormal CFR may represent a biomarker of micro-
ascular dysfunction due to effects of CAD risk factors (19),
hich may contribute to the pathogenesis of disease that
ill later lead to myocardial ischemia and events, thus
epresenting potential therapeutic targets (9). Although this
echanism is proposed by the authors, there is no coronary
natomy correlation to confirm this hypothesis. Do we
now for certain for a given patient whether global flow
eserve reduction is due to balanced 3-vessel CAD versus
icrovascular disease or both? The presence or absence of
elative perfusion abnormalities may favor the former or
atter, respectively. The severity of reduced CFR may also
elp. However, none of these features would be definitive,
o coronary anatomy definition may become necessary. In
atients with abnormal CFR without other high-risk fea-
ures on imaging, CT angiography (either independent or as
art of hybrid imaging) may play a valuable role.
How certain are we of the potential added value of flow
uantification in this study? The work of Herzog et al. (2)
as limitations that require consideration in this regard. The
tudy was observational and data were retrospectively ac-
uired. So, there is selection bias. Furthermore, although
he statistical methods are appropriate for defining indepen-
ent predictors, the sample size does not permit full use of
nteraction testing to help define the relationship between
erfusion score and CFR. In Table 2 and Figures 2 and 3 of
erzog et al. (2), we see that overall, there is an effect of
FR on outcomes for abnormal perfusion but, in fact, not
or normal perfusion patients. To be confident that the CFR
dded prognostic value in a subgroup, the interaction must
e considered. The authors state that there is no interaction
ffect of perfusion and CFR. However, the study was not
owered to be confident that no interaction exists. Without
n appropriately powered interaction analysis, it is difficult
o be definitive about the subgroup findings (20). Future
tudies should consider the guidelines proposed by Wang
t al. (21) so that interaction tests used to ensure theifferences between and within subgroups are considered
hen investigating the value added of one predictor over
nother.
Other unresolved issues include the prognostic value of
egional CFR that is not evaluated (acknowledged by the
uthors) and the selection of a cut-off value of CFR 2.
thers have suggested 2.5 (22). If 2 SDs from the mean in
normal population is selected, cut-points of 1.8 or lower
ould be selected (8,23). In the current study, patients with
CFR 2 are at increased risk for major adverse cardiac
vents and cardiac death, but more likely there is a contin-
um of risk. Larger studies will be needed to ascertain such
ncremental risk.
There is also uncertainty as to the best index of PET
uantitative flow analysis. CFR is most commonly used,
ut the myocardial stress-rest flow difference (or absolute
eserve) and hyperemic MBF have also been proposed
8 –10).
Finally, although 13NH3 is well validated, it is a short t½,
yclotron product, thus limiting its availability. The wider
pplication of CFR will likely require different tracers.
ecent data indicate that PET rubidium-82 (82Rb) is
easible to obtain accurate flow values (24,25), but the added
rognostic value of CFR using 82Rb PET has not been
ssessed. Novel 18F-labeled PET perfusion tracers are
romising (26–28) given the potential for wide distribution,
ut have not been validated in humans. Animal studies
sing gallium complexes (29) present the potential for long
½ generators. It is uncertain whether flow quantification
ith these new radiotracers will be possible. The importance
f quantifying flow has been realized, spawning investiga-
ion using other noninvasive technologies, magnetic reso-
ance imaging (30), computed tomography (31), and
PECT (32), with PET as the gold standard for compari-
on (8). Clinical utility is highly suspected but not yet
roven.
Herzog et al. (2) have brought us to the foot of the final
ath and taken a major step forward. The full clinical utility
f PET flow quantification will require larger prospective
tudies using more widely available tracers to determine its
mpact on decisions that affect outcomes, quality of life, or
osts. As noted by DeMaria (33), “Additional data on
omparative effectiveness should help us make better clinical
ecisions and result in better care for our patients.” The
ourney continues, with the end of the trail in sight.
eprint requests and correspondence: Dr. Rob S. B. Beanlands,
hief of Cardiac Imaging, Director, National Cardiac PET
entre, University of Ottawa Heart Institute, 40 Ruskin Street,
ttawa, Ontario K1Y 4W7, Canada. E-mail: rbeanlands@
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